Close

Gilead (GILD), Galapagos (GLPG) Announce Filgotinib Met Primary and All Key Secondary Endpoints in First Phase 3 Study in RA

September 11, 2018 4:07 PM EDT Send to a Friend
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login